Christopher Bryant Ph.D.

Dr. Bryant brings strong expertise in chemistry, manufacturing, and controls (CMC), pharmaceutical and combination product development, quality assurance and regulatory strategy with more than 30 years of experience in the research, development and approval of numerous marketed therapeutics. Dr. Bryant joined Halozyme in 2021 and is responsible for providing CMC leadership across all aspects of Halozyme programs.

Prior to Halozyme, Dr. Bryant served as Vice President of Technical Operations at Levo Therapeutics, Inc., where he was responsible for the development of drug substance and drug product CMC strategies. Prior to joining Levo, Dr. Bryant held similar positions in several private biotechnology start-ups. From 2009 to 2013 Dr. Bryant served as Chief Scientific Officer for Fresenius Kabi, USA overseeing the development of a broad range of complex injectable generic medicines. From 2003 until 2009 Dr. Bryant served as Chief Operating Officer in the development efforts for the plasma protein business at Prometic Biotherapeutics. Prior to joining Prometic, Dr. Bryant served in various research and development roles from 1993 to 2003 at Aventis Behring (now CSL Behring), where he supported numerous IND and BLA submissions as well as post-market life-cycle management efforts for MONOCLATE^®, MONONINE^® and ZEMAIRA^®.

Dr. Bryant received his B.A. in Chemistry from the University of Northern Iowa and his Ph.D. in Chemistry from the University of California, San Diego.